Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23952566 | 0.89 | RXFP1 (0.46) | RXFP1POLBTP53KMT2A | |
| SCHEMBL23952585 | 0.88 | POLB (0.42) | RXFP1POLBMAPTTHRBTP53 | |
| SCHEMBL25815956 | 0.76 | KCNH2 (0.35) | POLB | |
| SCHEMBL23952440 | 0.76 | NLRP3 (0.58) | RXFP1POLBMAPTTHRBTP53 | |
| SCHEMBL23952570 | 0.75 | NLRP3 (0.42) | RXFP1POLBTHRBTP53KMT2A | |
| SCHEMBL25818895 | 0.74 | NLRP3 (0.41) | RXFP1POLBMAPTTHRBTP53 | |
| SCHEMBL23952439 | 0.74 | MAPT (0.41) | RXFP1POLBMAPTTP53NLRP3 | |
| SCHEMBL23952043 | 0.71 | NLRP3 (0.46) | THRBKMT2ANLRP3 | |
| SCHEMBL25816781 | 0.70 | NLRP3 (0.45) | POLBMAPTTP53KMT2ANPC1 | |
| SCHEMBL25816710 | 0.67 | NLRP3 (0.51) | POLBTP53KMT2ANPC1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | RXFP1 647/4885POLB 3251/4885MAPT 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.